Company Description
Labcorp Holdings Inc. operates as a laboratory services company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions.
It operates in two segments, Diagnostics Laboratories (Dx) and Biopharma Laboratory Services (BLS). The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C and vitamin D, prostate-specific antigens, tests for sexually transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests.
It also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases; services related to anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing, occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests; and health and wellness services to employers and managed care organizations (MCOs), including health fairs, on-site and at-home testing, vaccinations, and health screenings.
In addition, the company offers online and mobile applications that enable patients to check test results; online applications for providers, MCOs, and accountable care organizations; and drug development, medical device, and companion diagnostic development solutions from early-stage research to clinical development, as well as support for crop protection and chemical testing.
It serves pharmaceutical, biotechnology, medical device, and diagnostics companies; and MCOs, employer plans, other health insurance providers, governmental agencies, physicians and other healthcare providers, hospitals and health systems, employers, patients and consumers, contract research organizations, crop protection and chemical companies, academic institutions, independent clinical la
| Country | United States |
| Founded | 1971 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Employees | 67,000 |
| CEO | Adam H. Schechter |
Contact Details
Address: 358 S Main St Burlington, North Carolina 27215 United States | |
| Phone | (336) 229-1127 |
| Website | labcorp.com |
Stock Details
| Ticker Symbol | LH |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000920148 |
| CUSIP Number | 50540R409 |
| ISIN Number | US50540R4092 |
| Employer ID | 99-2588107 |
| SIC Code | 8071 |
Key Executives
| Name | Position |
|---|---|
| Adam H. Schechter | President, Chief Executive Officer and Chairman |
| Glenn A. Eisenberg | Chief Financial Officer and Executive Vice President |
| Mark S. Schroeder | Executive Vice President, President of Diagnostics Laboratories and Chief Operating Officer |
| Dr. Brian J. Caveney J.D., M.D., M.P.H. | EVice President, President of Early Development Research Laboratories and Chief Medical and Scientific Officer |
| Anita Z. Graham | Executive Vice President and Chief Human Resources Officer |
| Peter J. Wilkinson | Senior Vice President and Chief Accounting Officer |
| Lance V. Berberian | Executive Vice President and Chief Information and Technology Officer |
| Christin O'Donnell | Vice President of Investor Relations |
| Sandra D. van der Vaart | Executive Vice President, Chief Legal Officer, Chief Compliance Officer and Corporate Secretary |
| Amy B. Summy | Executive Vice President and Chief Marketing Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 20, 2024 | 25-NSE | Filing |
| May 17, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| May 17, 2024 | S-3ASR | Automatic shelf registration statement of securities of well-known seasoned issuers |
| May 17, 2024 | POSASR | Filing |
| May 17, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| May 17, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| May 17, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| May 17, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| May 17, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| May 17, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |